Age-related macular degeneration: Current treatment and future options

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 5, 2011, Pages 325-331

  Moutray, Tanya ^a   Chakravarthy, Usha ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

age related macular degeneration; anti VEGF; choroidal neovascularization

Indexed keywords

AL 39324; AL 8309B; ARC 1905; BEVACIZUMAB; E 10030; GLATIRAMER; JM 6427; MAMMALIAN TARGET OF RAPAMYCIN; PEGAPTANIB; RANIBIZUMAB; RAPAMYCIN; STRONTIUM 90; TG 100801; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VERTEPORFIN; VITAMIN D; VOLOCIXIMAB; ZINC;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BRACHYTHERAPY; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RESEARCH; EARLY DIAGNOSIS; ENZYME INHIBITION; GENE THERAPY; GENETIC ASSOCIATION; HUMAN; LASER COAGULATION; LOADING DRUG DOSE; MONOTHERAPY; PATIENT EDUCATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION DOSE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; THROMBOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 81355132292     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311415895     Document Type: Review

References (43)

1. Arnon R. Aharoni R. (2009) Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm 116: 1443–1449.
2. Augustin A.J. Puls S. Offermann I. (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27: 133–140.
3. Avraamides C.J. Garmy-Sisini B. Varner J.A. (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604–617.
4. Brantley M.A. Fang A.M. King J.M. Tewari A. Kymes S.M. Shiels A. (2007) Association of complement factor H and LOC 387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114: 2168–2173.
5. Bressler N.M. Arnold J. Benchaboune M. Blumenkranz M.S. Fish G.E. Gragoudas E.S. et al (2002) Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes. TAP Report No. 3. Arch Ophthalmol 120: 1443–1454.
6. Brown D.M. Kaiser P.K. Michels M. Soubrane G. Heier J.S. Kim R.Y. et al for the ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432–1444.
7. Chakravarthy U. Augood C. Bentham G.C. de Jong P.T. Rahu M. Seland J. et al (2007) Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 114: 1157–1163.
8. Cukras C. Agron E. Klein M.L. Ferris F.L.III. Chew E.Y. Gensler G. et al for the Age-Related Eye Disease Study Research Group (2010) Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology 117: 489–499.
9. de Wan A. Lui M. Hartman S. Zhang S.S. Liu D.T. Zhao C. et al (2006) HTRA 1 promoter polymorphism in wet age-related macular degeneration. Science 314: 989–992.
10. Edwards A.O. Ritter R. Abel K.J. Manning A. Panhuysen C. Farrer L.A. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421–424.
11. Ferrara N. Davis-Smyth T. (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25.
12. Finkel T. Holbrook N.J. (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239–247.
13. Fisher S.A. Abecasis G.R. Yashar B.M. Zareparsi S. Swaroop A. Iyengar S.K. et al (2005) Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet 14: 2257–2264.
14. Gaudreault J. Fei D. Rusit J. Suboc P. Shiu V. (2005) Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46: 726–733.
15. Gold B. Merriam J.E. Zernant J. Hancox L.S. Taiber A.J. Gehrs K. et al (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38: 458–462.
16. Gragoudas, E.S., Adamis, A., Cunningham, E.T., Feinsod, M., Guyer, D.R. and for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816.
17. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P. et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419–421.
18. Haines J.L. Hauser M.A. Schmidt S. Scott W.K. Olson L.M. Gallins P. et al (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419–421.
19. Ham W.T. Jr Mueller H.A. Sliney D.H. (1976) Retinal sensitivity to damage from short wavelength light. Nature 260: 153–155.
20. Heier J.S. Boyer D.S. Ciulla T.A. Ferrone P.J. Jumper J.M. Gentile R.C. et al for the FOCUS Study Group (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124: 1532–1542. Erratum in: Arch Ophthalmol 2006; 125: 138.
21. Hughes A.E. Orr N. Esfandiary H. Diaz-Torres M. Goodship T. Chakravarthy U. (2006) A common CFH haplotype, with deletion of CFHR 1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 38: 1173–1177.
22. Juan-Babot J.O. Martınez-González J. Berrozpe M. Badimon L. (2003) Neovascularization in human coronary arteries with lesions of different severity. Rev Esp Cardiol 56: 978–986.
23. Khan J.C. Thurlby D.A. Shahid H. Clayton D.G. Yates J.R. Bradley M. et al (2006) Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90: 75–80.
24. Klein R. Klein B.E. Linton K.L. (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 933–943.
25. Lai T.Y. for the EVEREST Study Group (2010) Verteporfin PDT and ranibizumab combination therapy for symptomatic macular polypoidal choroidal vasculopathy (PCV): EVEREST results. Invest Ophthalmol Vis Sci 51: ARVO E–abstract 2228.
26. Leveziel N. Zerbib J. Richard F. Querques G. Morineau G. Fremeaux-Bacchi V. et al (2008) Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA 1 and CFH genotypes. Invest Ophthalmol Vis Sci 49: 3090–3094.
27. Ma X.M. Blenis J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307–318.
28. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109: 1109–1114.
29. Nguyen Q.D. Shah S.M. Browning D.J. Hudson H. Sonkin P. Hariprasad S.M. et al (2009) A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116: 2141–2148.
30. Owen C.G. Fletcher A.E. Donoghue M. Rudnicka A.R. (2003) How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 87: 312–317.
31. Rakic J.M. Lambert V. Devy L. Lutton A. Carmeliet P. Claes C. et al (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3186–3193.
32. Rivera A. Fisher S.A. Fritsche L.G. Keilhauer C.N. Lichtner P. Meitinger T. et al (2005) Hypothetical LOC 387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14: 3227–3236.
33. Rosenfeld P.J. Brown D.M. Heier J.S. Boyer D.S. Kaiser P.K. Chung C.Y. et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431.
34. Royal College of Ophthalmologists (2009) Age-Related Macular Degeneration. Guidelines for Management Royal College of Ophthalmologists: London.
35. Schmidt-Erfurth, U.M., Gabel, P., Hohman, T. for the PROTECT Study Group (2006) Preliminary results from an open-label, multicenter, phase II study assessing the effects of same-day administration of ranibizumab (Lucentis(TM)) and verteporfin PDT (PROTECT Study). In Program and Abstracts of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 30 April-4 May, abstract 2960.
36. Simons M. (2005) Angiogenesis: where do we stand now? Circulation 111: 1556–1566.
37. Singerman L.J. (2009) Advances in the management of dry age-related macular degeneration (AMD). Paper presented at the American Academy of Ophthalmology Annual Meeting San Francisco, CA, 24–27. October.
38. Thornton J. Edwards R. Mitchell P. Harrison R.A. Buchan I. Kelly S.P. et al (2005) Smoking and age-related macular degeneration: a review of associations. Eye 19: 935–944.
39. Tunón J. Ruiz-Moreno J.M. Mart´ın-Ventura J.L. Blanco-Colio L.M. Lorenzo O. Egido J. (2009) Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 54: 339–348.
40. Usui T. Ishida S. Yamashiro K. Kaji Y. Poulaki V. Moore J. et al (2004) VEGF164 (165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR 1 and VEGFR2. Invest Ophthalmol Vis Sci 45: 368–374.
41. Weger M. Renner W. Steinbrugger I. Köfer K. Wedrich A. Groselj-Strele A. et al (2007) Association of the HTRA 1 -625 G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population. Mol Vis 13: 1274–1279.
42. Wong T. Chakravarthy U. Klein R. Mitchell P. Zlateva G. Buggage R. et al (2008) The natural history and prognosis of neovascular age-related macular degeneration. A systematic review of the literature and meta-analysis. Ophthalmology 115: 116–126.
43. Yates J.R. Sepp T. Matharu B.K. Khan J.C. Thurlby D.A. Shahid H. et al (2007) Complement C 3 variant and the risk of age-related macular degeneration. N Engl J Med 357: 553–561.